Two diabetes companies have entered into a new agreement to research and license treatments for diabetes and cancer .
Pharmaceutical giant Pfizer Inc. have partnered with FivePrime Therapeutics to collaborate on developing treatments for the two diseases. FivePrime will screen their protein library with the intention of finding therapeutic protein products and targets for antibodies.
In return for this work FivePrime will accept an upfront payment and equity investment, as well as three years of commitment to research funding . Pfizer will hold exclusive global rights to develop and commercialise some of the products and targets created by the research.
Many big pharmaceutical companies hold exclusive research and development agreements with smaller scale biotechnology or therapeutics firms working in the same field. The opportunity allows smaller companies to grow, whilst providing larger companies with the potential to develop new products and expand their diabetic drug pipeline.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…